Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs ESGIC-PLUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
Esgic-Plus is a combination of acetaminophen (analgesic/antipyretic via COX inhibition and central action), butalbital (barbiturate that enhances GABA-A receptor activity), and caffeine (adenosine receptor antagonist and CNS stimulant). The mechanism for treating tension headache is attributed to the synergistic effects of these components.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Tension headache (FDA-approved)
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
1-2 capsules (acetaminophen 500 mg, butalbital 50 mg, caffeine 40 mg per capsule) orally every 4 hours as needed, not exceeding 6 capsules per day.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
Butalbital: 35-70 hours in adults; prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours in adults; extended in overdose (potential hepatotoxicity). Caffeine: 3-6 hours in adults; increased in pregnancy or liver disease.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Acetaminophen: primarily hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3); minor oxidation by CYP2E1, CYP3A4, and CYP1A2 to toxic NAPQI. Butalbital: hepatic via hydroxylation and glucuronidation; exhibits first-pass metabolism. Caffeine: hepatic via CYP1A2 (85%) to paraxanthine; also N-acetylation and oxidation.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Butalbital: 60-90% renal as unchanged drug and metabolites, 10-40% fecal via biliary elimination. Acetaminophen: ~85% renal as glucuronide (45-55%), sulfate (25-35%), and cysteine conjugates (4-15%); 2-4% unchanged. Caffeine: ~85-90% renal as metabolites (1-methylxanthine, 1-methyluric acid, 1,7-dimethylxanthine); 1-3% unchanged.
38-45%, primarily bound to albumin.
Butalbital: 25-30% bound to albumin. Acetaminophen: 10-25% bound to albumin (higher in overdose). Caffeine: 25-36% bound to albumin.
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
Butalbital: 0.5-0.8 L/kg, moderately tissue distributed. Acetaminophen: 0.7-1.0 L/kg, widespread including CNS. Caffeine: 0.5-0.7 L/kg, distributed in total body water.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Oral: Butalbital ~85-95%; Acetaminophen ~75-85% (first-pass metabolism); Caffeine ~99% (almost complete).
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
GFR 30-89 m L/min: No adjustment. GFR 15-29 m L/min: Extend interval to every 6 hours; avoid in severe impairment (GFR <15 m L/min) due to butalbital accumulation.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% or extend interval to every 6 hours. Child-Pugh C: Contraindicated due to risk of hepatic encephalopathy and acetaminophen toxicity.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
Not recommended for pediatric patients; safety and efficacy not established. For children >12 years, consider adult dosing on a case-by-case basis.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
Initiate at lower dose (1 capsule every 6 hours) and monitor for sedation, confusion, or hepatotoxicity. Reduce total daily dose if renal or hepatic impairment present.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Hepatotoxicity: avoid exceeding 4000 mg acetaminophen per day; severe liver injury may occur with chronic use even at therapeutic doses.,Respiratory depression: butalbital can cause dose-related respiratory depression.,Drug dependence: butalbital has abuse potential and may cause withdrawal syndrome upon discontinuation.,Interaction with alcohol: increased risk of hepatotoxicity with chronic alcohol use.,Renal impairment: use with caution in severe impairment.,Pregnancy: avoid use, especially during third trimester, due to potential neonatal withdrawal and respiratory depression.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Hypersensitivity to any component,Acute intermittent porphyria (butalbital),Severe hepatic impairment,Concurrent use of other acetaminophen-containing products (risk of overdose),Breastfeeding (butalbital and caffeine pass into breast milk and may cause adverse effects in the infant)
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
Avoid alcohol. Limit caffeine-containing foods and beverages (coffee, tea, cola, chocolate) to prevent additive stimulant effects. No significant food-drug interactions otherwise.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
FDA Pregnancy Category C. First trimester: butalbital is associated with increased risk of congenital malformations (cleft palate, urogenital anomalies) based on barbiturate class effects; acetaminophen and caffeine are generally considered low risk. Second/third trimester: prolonged use may lead to neonatal withdrawal (irritability, tremors) and potential neonatal hemorrhage (due to acetaminophen's effect on vitamin K-dependent clotting factors).
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Acetaminophen and caffeine enter breast milk in small amounts (M/P ratio ~0.1-0.2 and 0.5-0.7 respectively); butalbital is excreted with M/P ratio ~0.5. Concentrations are low, but risk of neonatal sedation and withdrawal with chronic use. Not recommended unless benefit outweighs risk.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
No specific dose adjustments established; use lowest effective dose for shortest duration. Increased clearance of acetaminophen and caffeine may occur in pregnancy, but clinical significance is unknown; avoid chronic use.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
ESGIC-PLUS combines acetaminophen, butalbital, and caffeine. Butalbital is a barbiturate with abuse potential; limit use to 5 days to avoid tolerance and dependence. Acetaminophen content (325-500 mg) requires caution not to exceed 4 g/day due to hepatotoxicity risk. Caffeine may exacerbate anxiety or insomnia. Monitor for sedation when used with other CNS depressants.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Take exactly as prescribed; do not exceed dosage or duration.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids).,Do not take other acetaminophen-containing medicines to prevent overdose.,May cause drowsiness or dizziness; avoid driving or operating machinery.,Limit caffeine intake from other sources (coffee, tea, soda) to avoid overstimulation.,Seek medical help if you experience signs of liver damage (yellow skin/eyes, dark urine) or severe skin reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs ESGIC-PLUS, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. ESGIC-PLUS is a Barbiturate/Narcotic Combination that works by Esgic-Plus is a combination of acetaminophen (analgesic/antipyretic via COX inhibition and central action), butalbital (barbiturate that enhances GABA-A receptor activity), and caffeine (adenosine receptor antagonist and CNS stimulant). The mechanism for treating tension headache is attributed to the synergistic effects of these components.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and ESGIC-PLUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of ESGIC-PLUS is: 1-2 capsules (acetaminophen 500 mg, butalbital 50 mg, caffeine 40 mg per capsule) orally every 4 hours as needed, not exceeding 6 capsules per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and ESGIC-PLUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. ESGIC-PLUS is classified as Category C. FDA Pregnancy Category C. First trimester: butalbital is associated with increased risk of congenital malformations (cleft palate, urogenital anomalies) based on barbiturate class . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.